How Long Can Folinic Acid Rescue Be Delayed After High-Dose Methotrexate Without Toxicity?

被引:31
作者
Cohen, Ian Joseph [1 ,2 ]
Wolff, Johannes E. [3 ]
机构
[1] Rabin Med Ctr, Raphael Recanati Genet Inst, Petah Tiqwa, Israel
[2] Tel Aviv Univ, Sackler Fac Med, IL-69978 Tel Aviv, Israel
[3] Tufts Med Ctr, Floating Childrens Hosp Children, Dept Pediat Hematol Oncol, Boston, MA USA
关键词
dose; folinic acid; leucovorin rescue; methotrexate; timing; ACUTE LYMPHOBLASTIC-LEUKEMIA; PEDIATRIC-ONCOLOGY-GROUP; ACUTE LYMPHOCYTIC-LEUKEMIA; INTRAVENOUS METHOTREXATE; CLINICAL-PHARMACOLOGY; REMISSION INDUCTION; CHILDREN; CHEMOTHERAPY; THERAPY; NEUROTOXICITY;
D O I
10.1002/pbc.24770
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
To determine the optimal time of folinic acid rescue after methotrexate (MTX) treatment in patients with ALL, we selected and evaluated relevant studies that included doses, rescue delay, and side effects. Rescue at 42-48hours resulted in considerable toxicity, except when low doses of MTX were used (1g/m(2)) or serum MTX levels remained consistently low at 24, 30, and 36hours. Rescue started at 30-36hours was safe. In the absence of evidence that later rescue improves prognosis, we suggest that folinic acid rescue (105mg/m(2)) be started no later than 36hours from the start of MTX (5-6g/m(2)). Pediatr Blood Cancer 2014;61:7-10. (c) 2013 Wiley Periodicals, Inc.
引用
收藏
页码:7 / 10
页数:4
相关论文
共 42 条
[1]  
Amparo Buendia MT, 2008, J PEDIAT HEMATOL ONC, V30, P643
[2]   REMISSION INDUCTION OF MENINGEAL LEUKEMIA WITH HIGH-DOSE INTRAVENOUS METHOTREXATE [J].
BALIS, FM ;
SAVITCH, JL ;
BLEYER, WA ;
REAMAN, GH ;
POPLACK, DG .
JOURNAL OF CLINICAL ONCOLOGY, 1985, 3 (04) :485-489
[3]  
Bell B., 1997, Blood, V90, p559A
[4]  
BERTINO JR, 1977, SEMIN ONCOL, V4, P203
[5]   INDUCTION OF DIHYDROFOLIC REDUCTASE ACTIVITY IN LEUKOCYTES AND ERYTHROCYTES OF PATIENTS TREATED WITH AMETHOPTERIN [J].
BERTINO, JR ;
GABRIO, BW ;
DONOHUE, DM ;
SILBER, R ;
SIMMONS, B ;
HUENNEKENS, FM .
JOURNAL OF CLINICAL INVESTIGATION, 1963, 42 (04) :466-&
[6]   ODE TO METHOTREXATE [J].
BERTINO, JR .
JOURNAL OF CLINICAL ONCOLOGY, 1993, 11 (01) :5-14
[7]   METHOTREXATE - CLINICAL PHARMACOLOGY, CURRENT STATUS AND THERAPEUTIC GUIDELINES [J].
BLEYER, WA .
CANCER TREATMENT REVIEWS, 1977, 4 (02) :87-101
[8]  
BLEYER WA, 1978, CANCER-AM CANCER SOC, V41, P36, DOI 10.1002/1097-0142(197801)41:1<36::AID-CNCR2820410108>3.0.CO
[9]  
2-I
[10]  
BONDASHKEDI E, 2013, PEDIATR HEMAT ONCOL, V35, P271